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Silencing of Jagged1 inhibits cell growth and invasion
in colorectal cancer
Y Dai1,8, G Wilson2,8, B Huang3,8, M Peng3, G Teng1, D Zhang3, R Zhang*,3, MPA Ebert4, J Chen*,5, BCY Wong6, KW Chan7, J George2
and L Qiao*,2
Dysregulated Notch signaling has a critical role in the tumorigenesis. Jagged1, a Notch ligand, is overexpressed in various
human cancers. Recent studies revealed the involvement of Jagged1 in colorectal cancer (CRC) development. These basic
studies provide a promising potential for inhibition of the Notch pathway for the treatment of CRC. Herein, we aimed to
investigate the consequences of targeting Jagged1 using shRNA on CRC both in vitro and in vivo to test their potential to inhibit
this key element for CRC treatment. We found that downregulation of Jagged1 with lentiviral Jagged1-shRNA resulted in
decreased colon cancer cell viability in vitro, most likely mediated through reduced cell proliferation. Importantly, Jagged1
knockdown induced G0/G1 phase cell cycle arrest, with reduced Cyclin D1, Cyclin E and c-Myc expression. Silencing of Jagged1
reduced the migration and invasive capacity of the colon cancer cells in vitro. Furthermore, colon cancer cells with knockdown
of Jagged1 had much slower growth rate than control cells in a xenograft mouse model in vivo, with a marked downregulation of
cell proliferation markers (PCNA, Ki-67, and c-Myc) and metastasis markers (MMP-2 and MMP-9). These findings rationalize a
mechanistic approach to CRC treatment based on Jagged1-targeted therapeutic development.
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Colorectal cancer (CRC) is the third most common malig-
nancy in males and second most common in females
worldwide.1 The highest incidence of CRC is found in
Australia, New Zealand and North America, and the morbidity
is rapidly increasing in Eastern Asia and Eastern Europe.2,3
About 40–50% of all patients with CRC will present with
metastasis either at the time of diagnosis or develop distant
relapses after therapy, and the median overall survival of
metastatic CRC is less than 2 years.4 Current therapeutic
options for advanced CRC, such as chemotherapy and
radiotherapy, only have limited efficacy and can barely
improve patient survival. A better understanding of the
molecular mechanisms involved in CRC development and
progression is imperative for the improvement of therapeutic
approaches that can benefit patients with CRC.
The Notch signaling has an important role in cell growth and
differentiation, which affects the development and function of
many organs.5,6 Notch receptors (Notch1–4 in humans) are a
group of transmembrane proteins in many cell types. Binding
to their ligands (Jagged1, 2 and delta-like ligand (DLL) 1, 3,
and 4) on the surface of neighboring cells leads to the
cleavage of Notch receptor by g-secretase and subsequent
release of the Notch intracellular domain (NICD). As the
constitutively active domain of the Notch receptor, NICD can
translocate to the nucleus, where it binds to and forms a
complex with the transcriptional regulator termed CBF-1-Su
(H), and LAG-1 (CSL) or RBP-Jeˆ, leading to the displacement
of co-repressors previously bound to CSL and recruitment of
co-activators. The co-activators then induce expression of the
target genes, such as the hairy and enhancer of split (Hes)
and Hes-related repressor protein (Hey) families. Accumulat-
ing evidences indicate that dysregulated Notch pathway has a
critical role in the progression of several malignancies such as
prostate cancer, breast cancer, glioma and head and neck
cancers. Furthermore, high expression levels of several key
members of the Notch cascade such as Notch1 and Jagged1
1Department of Gastroenterology, Peking University First Hospital, Beijing, China; 2Storr Liver Unit, Westmead Millennium Institute, Department of Medicine and
Western Clinical School, The University of Sydney, Westmead, NSW, Australia; 3Research Center of Basic Medical Sciences and Department of Immunology, Key
Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Medical University, Tianjin, China; 4Department of Medicine II, Klinikum
Rechts der Isar, Technical University, Munich, Germany; 5School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia; 6Departments of
Medicine, The University of Hong Kong, Pokfulam, Hong Kong and 7Departments of Pathology, The University of Hong Kong, Pokfulam, Hong Kong
*Corresponding author: R Zhang, Research Center of Basic Medical Sciences and Department of Immunology, Key Laboratory of Immune Microenvironment and
Diseases of Educational Ministry of China, Tianjin Medical University, Tianjin 300070, China. Tel/Fax: þ 86 22 83336563; E-mail: rongxinz@yahoo.com
or J Chen, School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. Tel: +61 7 3365 1409; Fax: +61 7 3365 1766;
E-mail: j.chen4@uq.edu.au
or L Qiao, Storr Liver Unit, Westmead Millennium Institute, Department of Medicine and Western Clinical School, The University of Sydney, Westmead, NSW 2145,
Australia. Tel: þ 61 2 9845 9132; Fax: þ 61 2 9845 9103; E-mail: liang.qiao@sydney.edu.au
8These authors contributed equally to this paper.
Received 05.1.14; revised 18.2.14; accepted 26.2.14; Edited by G Raschella´
Keywords: colorectal cancer; Notch signaling; Jagged1; targeting; xenograft tumors
Abbreviations: Apex, purinic–apyrimidinic endonuclease-1; CDK, cyclin-dependent kinase; CRC, colorectal cancer; DLL, delta-like ligand; Hes, hairy and enhancer of
split; Hey, Hes-related repressor protein; L-Jagged1-shRNA, lentiviral Jagged1-shRNA; MMP, matrix metalloproteinase; NICD, notch intracellular domain; PCNA,
proliferating cell nuclear antigen
Citation: Cell Death and Disease (2014) 5, e1170; doi:10.1038/cddis.2014.137
& 2014 Macmillan Publishers Limited All rights reserved 2041-4889/14
www.nature.com/cddis
are associated with increased progression and metastatic
potential, recurrence and a poorer overall survival.7–11
Recently, Lu et al.12 showed endothelial cells could secrete
Jagged1 and mediate the activation of Notch signaling in CRC,
leading to increased expression of Hes1. Kim et al.13 demon-
strated that Jagged1 was a mediator of a purinic–apyrimidinic
endonuclease-1 (apex)-induced CRC progression.
The role of Notch signaling in the development of CRC has
attracted wide attention over the past few years.14 Animal
studies have shown that Notch is active in intestinal crypts and
adenomas in APCMin/þ mice.15 Moreover, deletion of one
Jagged1 allele is sufficient to significantly reduce the size of
tumors in the APC mutant background concomitant with a
reduction in the amount of active Notch1.16 It was shown that
Notch signaling is strongly activated in primary human CRC
and has an important role in the initiation and progression of
CRC through the regulation of the main cellular functions
associated with tumorigenesis, such as apoptosis, prolifera-
tion, angiogenesis, and cell migration.17–19 Thus, the Notch
pathway has been regarded as an attractive target for CRC
therapy.20,21 One approach currently being explored in clinical
trials is blocking the cleaving process of Notch receptors with
g-secretase inhibitors. These agents have shown the ther-
apeutic benefit for CRC.22 Although g-secretase inhibitors are
valuable tools for delineating the function of Notch cascade,
they were found to be not specific for Notch signaling and were
associated with various adverse effects such as gastrointest-
inal toxicity and liver injury.23 Notch downregulation is
fundamental in driving secretory cell differentiation in the
normal intestinal mucosa15,24,25 thus, inactivation of the Notch
signaling causes secretory cell metaplasia, and results in
inflammatory response.25 The efficacy of this class of
compounds needs exploring, but the relative lack of target
specificity suggests that new and more specific strategies
targeting this pathway should be pursued. A recent study has
demonstrated that inactivation of DLL1 and DLL4-mediated
Notch signaling results in loss of intestinal proliferating
progenitors due to conversion into postmitotic goblet cells,
but inducible deletion of Jagged1 has no overt phenotype.26
Moreover, expression of Jagged1 was restricted to enter-
oendocrine cells or undetectable in the mucosa of the human
small and large intestine, respectively. In contrast, increased
expression was found in human colon tumors.20 These data
suggest that Jagged1 may be a more specific target molecule
for developing new therapy against CRC.
As most studies have focused on the effects of inhibiting the
Notch receptor and its downstream signaling, specific inhibi-
tion of Jagged1 in CRC has not been fully explored. In this
study, we aimed to determine the efficacy of specific targeting
of Jagged1 as a therapeutic approach for CRC. In vitro and
in vivo models were utilized to investigate the effects of
Jagged1 knockdown on cell viability and invasion in CRC.
Results
High expression of Jagged1 in human CRC tissues was
associated with activation of the Notch pathway. We first
examined the expression of Jagged1 in 24 pairs of human
colon cancer tissues and matched non-cancerous colonic
mucosa by qPCR. As shown in Figure 1a, the majority
(20/24, or 83%) of cancer tissues (tumor) exhibited higher
expression level of Jagged1 relative to their corresponding
non-cancerous controls (normal). Figure 1b shows that the
average expression of Jagged1 mRNA was B6-fold higher
in tumor tissues than in normal tissues (Po0.01). Higher
expression levels (42.5-fold) of Jagged1 protein in colon
cancer tissues were also confirmed by immunohisto-
chemistry (Figures 1c and d). The increased Jagged1
expression in tumor tissues was associated with activation
of Notch signaling, with an increased expression of Notch
target gene Hes1 (Figure 1e). These data confirm that
Jagged1 is frequently overexpressed in CRC and likely
responsible for the constitutive activation of Notch signaling,
implying that selectively, targeting this protein may present
a novel therapeutic strategy in CRC. Therefore, we
designed shRNA and packaged it into a lentiviral vector to
generate lentiviral Jagged1-shRNA (L-Jagged1-shRNA),
and the efficacy of this vector-mediated Jagged1 knock-
down against CRC was tested in a series of in vitro and
in vivo assays.
Knockdown of Jagged1 led to reduced Notch signaling
activity in CRC cells. Protein expression of Jagged1, as
measured by western blot, was prominent in human colon
cancer cell lines HCT15, HT29, DLD1, HCT116 and SW480
(Figure 2a). When these colon cancer cells were infected
with L-Jagged1-shRNA for 72 h, there was a marked
reduction in the expression of endogenous Jagged1
(Figure 2b), confirming a successful gene knockdown.
Importantly, silencing Jagged1 was sufficient to significantly
decrease the expression of Hes1 at both mRNA and protein
levels, as exemplified in HT29 cells (Figures 2c and d,
respectively), suggesting that the expression of Jagged1 is a
general characteristic of colon cancer cell lines, and that
Jagged1 knockdown causes Notch signaling activity
inhibition.
Downregulation of Jagged1 induced cell growth inhibition
and G0/G1 cell cycle arrest in colon cancer cells. Given
the increased expression of Jagged1 in the CRC tissues and
colon cancer cell lines, we determined whether Jagged1
downregulation affected colon cancer cell proliferation
in vitro. HCT15, HT29, DLD1 and HCT116 cells
were transiently transfected with L-Jagged1-shRNA or
scrambled-shRNA for 24 h, and cell viability was assessed
by [3H]-thymidine incorporation assay 72 h later. As shown in
Figure 3a, Jagged1 downregulation decreased cell viability
by 39%, 58%, 47%, and 41% in HCT15, HT29, DLD1, and
HCT116 cells, respectively. In addition, Jagged1 knockdown
cells exhibited decreased anchorage-dependent growth
property. The clonogenicity was reduced by 76%, 62%, and
85% in HCT15, HCT116, and SW480 cells, respectively
(Figure 3b), indicating that downregulation of Jagged1
suppressed colon cancer cell proliferation.
To determine the mechanism by which Jagged1 down-
regulation may affect cell growth, cells were infected with
L-Jagged1-shRNA or scrambled-shRNA, and cell cycle
analysis was carried out. As shown in Figure 4b, knockdown
of Jagged1 led to decrease in the percentage of SW480 cells
in S phase by nearly 10% and increased the G0/G1 fraction
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Figure 1 Expression of Jagged1 by qPCR in 24 pairs of colon cancer (tumor) and matched non-cancerous colonic tissues (normal) (a). On average, higher expression
level of Jagged1 was found in tumor than in normal tissues (n¼ 24, b). In seven selected cases, higher expression of Jagged1 in tumor tissues was confirmed by
immunohistochemistry (n¼ 7, c, d). Expression of Notch downstream target gene Hes1was examined by qPCR in cancerous (tumor) and matched non-cancerous (normal)
colon tissues (e). **Po0.01
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Figure 2 Expression of Jagged1 was determined by western blot in five colon cancer cell lines (a). L-Jagged1-shRNA successfully knocked down Jagged1 in these cells
(b). Downregulation of Jagged1 was associated with a reduced expression of Notch downstream target Hes1 in HT29 cells at the mRNA (c) and protein levels (d). *Po0.05.
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from 39.23% to 61.58%, indicating a G0/G1 cell cycle arrest.
A similar result was found in HCT15 cells (data not shown).
Furthermore, cell cycle-related protein expression was
assessed by western blot. Consistent with the accumulation
of cells in G0/G1 phase, Cycline D1, Cyclin E, and c-Myc
significantly decreased in L-Jagged1-shRNA-treated HCT15
and SW480 cells, whereas Cyclin A remained unchanged,
compared with scrambled-shRNA-treated cells (Figure 4a). In
addition, there was no significant increase in apoptosis upon
Jagged1 knockdown in HCT15, HCT116, and SW480 cells as
detected by AnnexinV/PI staining (data not shown). Together,
these results indicated that Jagged1 silencing in colon cancer
cells was associated with a block in cell cycle progression and
not increased apoptosis.
Downregulation of Jagged1 decreased the migration
and invasion capacity of colon cancer cells. Elevated cell
migration and invasion are associated with increase in the
metastatic potential of cancer cells. This may be independent
of cell proliferation rates. Therefore, we studied the effect of
Jagged1 downregulation on the migration and invasion of
colon cancer cells. Cell migration was determined by wound-
healing assay. As shown in Figure 5a, Jagged1 down-
regulation significantly suppressed the migration of HCT116
cells. The migration index of Jagged1 knockdown cells was
decreased by 49%, 47%, and 36% at 24, 48, and 72 h,
respectively (Figure 5b). To examine the cell invasion activity
in vitro, we used transwell inserts coated with matrigel matrix.
After Jagged1 knockdown, the invasiveness of HCT116 cells
was decreased by 43% as compared with the control cells
(Figures 5c and d).
Silencing of Jagged1 suppressed the growth of xenograft
tumors in nude mice. To explore the effects of Jagged1
knockdown in vivo, xenograft tumors were generated by
injecting HCT15 cells stably infected with either control
vector (scrambled-shRNA) or L-Jagged1-shRNA. The cells
were injected s.c. into the flanks of nude mice. As shown in
Figure 6a, tumors derived from HCT15 cells previously
infected by scrambled-shRNA grew fast, particularly 13 days
after injection. Compared with the control group, tumors
derived from L-Jagged1-shRNA-infected cells grew much
slower throughout the experiment, suggesting that knock-
down of Jagged1 dramatically impaired the tumorigenic
growth of HCT15 cells. At harvest, the tumors from
L-Jagged1-shRNA-infected cells weighed much lighter than
those from control cells (48-fold) (Figure 6b). The average
volume of tumors derived from Jagged1 knockdown cells
showed B10-fold reduction compared with control (Figures
6c and d).
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To further verify the antitumor effects of Jagged1 silencing,
we next examined the expression of cell proliferation markers
(Ki-67, PCNA, c-Myc), metastasis markers (MMP-9, MMP-2)
and angiogenesis marker CD31 at the mRNA and protein
levels in xenograft tumors. As shown in Figure 7a, there was a
significant reduction in the mRNA expression of Ki-67, PCNA,
c-Myc, MMP-9, and MMP-2 in tumor tissues. The mRNA level
of CD31 in tumors was not altered upon Jagged1 knockdown.
Immunohistochemical staining confirmed these findings, as
exemplified by the reduced Ki-67 and MMP-9 expression in
the xenograft tumors derived from HCT15 cells infected by
L-Jagged1-shRNA (Figure 7b).
Discussion
In the current study, we found that Jagged1, one of the most
important ligands for the Notch signaling, is overexpressed in
B80% of human CRC tissues, and is associated with a
marked elevated expression of Notch target gene Hes1.
Targeting Jagged1 induces growth inhibition in colon cancer
cells both in vitro and in vivo, at least in part by causing G0/G1
phase cell cycle arrest. In addition, downregulation of
Jagged1 reduces the migration and invasion of colon cancer
cells, most likely involving decreased MMPs.
Notch signaling is critical for determination of cell fate within
a wide variety of tissues by regulation of growth, differentia-
tion, and apoptosis. Abnormal Notch signaling is associated
with tumorigenesis7–11 and cell invasion.11,27–29 Previous
studies have shown aberrant expression of the Notch path-
way in CRC.16,20,30 In particular, Jagged1 was found to be
overexpressed inB50% of human colon tumors, while it was
undetectable in the normal colonic mucosa.20 Moreover, the
levels of Jagged1 expression were correlated with tumor
differentiation parameters and stages of CRC.30,31 It was
found that high expression of Jagged1 is associated with poor
clinical outcome in some malignancies such as breast cancer
and prostate cancer, whereas another study demonstrated
high Jagged1 levels were correlated with better prognosis of
CRC.31 The association and prognostic value of Jagged1 in
CRC remains to be investigated further. In this study, we
confirmed that480% of CRC tissues expressed higher level
of Jagged1 compared with normal colonic tissues, and that
this was associated with a marked elevated expression of the
Notch target gene Hes1. These data suggested that Jagged1
is likely a major ligand responsible for Notch signaling
activation in CRC, and that selective targeting of this protein
may present a novel therapeutic strategy.
We demonstrated that lentiviral vectors carrying Jagged1-
shRNA-mediated Jagged1 silencing effectively blocked the
Notch signaling in colon cancer cells, as reflected by a strong
inhibition of Notch target genes. Downregulation of Jagged1
expression led to a reduced cell proliferation, colony forma-
tion, migration, and invasion. In vivo studies showed that
xenograft tumors derived from Jagged1 knockdown cells
displayed a significant reduction of growth speed and tumor
volume, suggesting that direct downregulation of Jagged1 has
an antitumor effect in colon cancer.
Notch signaling influences cell proliferation depending on the
cell type. For example, the Notch1 pathway has been found to
have a tumor-suppressive effect on murine skin tumor and
small cell lung cancer.32,33 However, Notch1 appears to
function as an oncogene in several human cancers.7–11 It has
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been reported that Jagged1 is processed in a fashion similar
to Notch1, ultimately resulting in the release of a nuclear
targeted intracellular domain.34 Thus, Jagged1 is itself
important in development and carcinogenesis. Here we found
that downregulation of Jagged1 attenuated the growth of
colon cancer cells and that this was associated with retarded
cell cycle progression. The in vivo results also showed that
Jagged1 knockdown dramatically impaired the tumorigenic
growth of HCT15 cells. In agreement with this, we found a
reduction in the number of Ki-67-positive cells in the tumors
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derived from Jagged1 knockdown cells compared with
the ones from the control cells. Taken together, these
observations suggested a positive role of Jagged1 in colon
cancer cell growth and that Jagged1 may function as an
oncogene in CRC.
The cell cycle is regulated by a series of checkpoints
monitoring genomic integrity and ensuring that DNA replica-
tion proceeds in a coordinated manner. Aberrations in cell
cycle progression occur in the majority of human malignan-
cies. Different combinations of cyclin and CDK subunits
operate at checkpoint controls during the cell cycle to
integrate mitogenic and antiproliferative signals. Cyclin D1
and Cyclin E have a critical role in controlling G1/S
transition.35 The present study indicates that downregulation
of Jagged1 causes G0/G1 phase cell cycle arrest via a
reduction of Cyclin D1 and Cyclin E levels, which appears to
be the underlying mechanism in colon cancer cell growth
inhibition. c-Myc is also important in cell cycle regulation and
tumorigenesis.36,37 Jagged1 knockdown reduced c-Myc
expression, so it might also contribute to the G0/G1 phase
arrest. It was shown that regulation of the cell cycle by Notch
signaling involves the coordination of different, and some-
times antagonizing, pathways in a highly cell context-
dependent manner. Our observation was in line with the
previous study by others20 that inhibition of Notch signaling by
g-secretase inhibitors resulted in G1 phase arrest in colon
cancer cells. However, downregulation of Jagged1 induced S
phase arrest in prostate cancer cells with reduced CDK2
kinase activity and increased p27 expression.38 On the other
hand, Jagged1 knockdown results in an accumulation of
ovarian cancer cells in the G2–M phase,39 suggesting the
control of cell cycle progression by Jagged1 is cell-type
specific.
Previous studies have shown that constitutively activated
Notch signaling is involved in apoptosis resistance, and that
abrogating Notch activation by the g-secretase inhibitor,
Notch1-siRNA, and DLL1-siRNA can induce apoptosis in
human cancer cells.40,41 However, in the present study, a very
mild apoptosis was detected in colon cancer cells upon
Jagged1 knockdown both in vitro and in vivo. These findings
are partially consistent with another report that Jagged1-
shRNA leads to significant cell growth inhibition in ovarian
cancer cells but to a minor extent of apoptosis.42 We
speculate that several key members of the Notch cascade
have different roles in apoptosis, and induction of apoptosis is
not a major mechanism for targeting Jagged1-mediated Notch
signaling activation in CRC.
The Notch pathway was found to participate in many
aspects of metastasis, the epithelial to mesenchymal transi-
tion, cell migration, invasion, and angiogenesis.43,44
g-Secretase inhibitors were shown to reduce cell migration
in different cancer cell lines.45 A recent report has shown that
tumor-derived Jagged1 promotes bone metastasis of breast
cancer.11 It is noteworthy that, in our study, downregulation of
Jagged1 significantly reduced the migration and invasion in
colon cancer cells, and was associated with decreased
expression of MMP-2 and MMP-9. MMP-2 and MMP-9 belong
to the family of matrix metalloproteinases, and are present
in invasive CRC.46 The expression of these enzymes is
known to be regulated by Notch signaling in cancer cells.
For instance, downregulation of Notch1 decreases MMP-9
levels in pancreatic cancer cells27 and prostate cancer cells.29
Here, we detected a decreased level of MMP-2 and MMP-9
upon Notch1 knockdown, suggesting that Jagged1 probably
affects cell invasion via its action on the production of matrix-
degrading enzymes. Although further studies are necessary
to fully characterize the roles of Notch signaling in metastasis
of CRC, the inhibitory effect of Jagged1 knockdown on colon
cancer cell migration is of particular interest, and Jagged1
may be a useful target molecule for developing new therapy
against CRC.
Previous studies have shown that Jagged1 may have its
own signaling function that is important to tumorigenesis
independent of the canonical Notch pathway.39 Our study has
demonstrated that Jagged1 targeting led to a marked
reduction in the expression of Notch downstream target
Hes1, suggesting that downregulation of Jagged1-mediated
antitumor effect was at least partly through a Notch-
dependent mechanism in colon cancer cells. Since systemic
inhibition of Notch signaling by g-secretase inhibitors is
associated with adverse effects such as gastrointestinal
toxicity and liver injury, Jagged1 may possibly constitute a
promising target for CRC patients. It was noted that delivery of
lentiviral vectors to patients may be practically impossible
because protecting normal cells from being infected by the
virus is a demanding task. Nanoparticles have been
demonstrated to transport siRNA across cellular membranes
and are biodegradable, biocompatible, and have low immuno-
genicity.47,48 Nanoparticles have been used to carry siRNAs
against certain oncoproteins for the treatment of melanoma
in a phase I clinical trial and showed no dose limiting
cytotoxicity.48 Moreover, targeting Jagged1 using this delivery
system decreased cell viability and reversed taxane
chemoresistance in ovarian cancer cells.39 Thus, our results
establish a foundation on which targeted therapy can be
developed.
In conclusion, we have shown that targeting Jagged1
inhibits proliferation, migration, and invasion of colon cancer
cells in vitro, as well as suppresses the tumor growth and
decreases tumor load in nude mice. With the ability to identify
subsets of cancer patients with Jagged1 overexpression,
antagonism of this signaling molecule could ultimately provide
a useful therapeutic strategy for CRC.
Materials and Methods
Chemicals, reagents, and cell lines. Human colon cancer cell lines
HCT15, HCT116, HT29, DLD1, and SW480 were purchased from the American
Type Culture Collection (Manassas, VA, USA). Trizol, PCR-related reagents, and
all cell culture-related materials were purchased from Invitrogen (Carlsbad, CA,
USA). All the primary antibodies except anti-c-Myc (BD Biosciences, San Jose,
CA, USA), anti-GAPDH (Abcam, Cambridge, UK) and anti-Ki-67 (DAKO, Glostrup,
Denmark), and secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Detection of Jagged1 in human colon cancer tissues by tissue
microarray (TMA). Tissue microarray and fresh human CRC tissues and
matched non-cancerous colonic tissues were described in detail in our previous
publication.49 These cancer tissues were largely obtained from patients who
underwent surgical operations for CRC. All cancer tissues, matched non-
cancerous tissues, and TMAs were provided by M Ebert of the Technical
University, Munich, Germany. In the current study, all 24 tissues were
adenocarcinomas, and classified into well (n¼ 3), moderately (n¼ 18), and
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poorly (n¼ 3) differentiated. Patient ages ranged from 49 years to 77 years
(mean, 64 years), consisting of 16 males and 8 females.
The expression of Jagged1 was detected by immunohistochemistry in TMA
slides, as reported in our previous publications.49 The slides were evaluated by a
senior pathologist (KW Chan), and the quantitative score was generated as
previously reported.49,50 The study was approved by the institutional human ethics
committee of the relevant institutions.
Construction of recombinant lentiviral vectors. A 21-mer oligo-
nucleotide sequence from nucleotide 1496 to 1516 of the Jagged1 human mRNA
sequence was used. The hairpin sense and antisense sequences were as follows:
50-CCGGTGGTATTCAGGACCCAACTGTGCTCGAGCACAGTTGGGTCCTGAAT
ACCTTTTTG-30 and 50-AATTCAAAAAGGTATTCAGGACCCAACTGTGCTCGAG
CACAGTTGGGTCCTGAATACCA-30. The oligonucleotides were annealed and
cloned into the AgeI/EcoR1 sites of the shRNA vector pLKO.1-puro (Addgene,
Cambridge, MA, USA). Expression of the shRNA was controlled by the human U6
promoter. To produce lentiviral particles, the constructed Jagged1-shRNA or
scrambled-shRNA plasmid was co-transfected with psPAX2 packaging plasmid
and pMD2.G envelope plasmid into 293T cells using X-tremeGENE HP DNA
transfection Reagent (Roche, Basel, Switzerland). The titer of the purified virus
was determined in 293T cells by the serial dilution method.
Cell culture and construction of Jagged1 knockdown cells.
Human colon cancer cell lines HCT116, HCT15, HT29, DLD1, and SW480
were cultured in RPMI1640 medium supplemented with 10% FBS and
1% Pen-Strep at 37 1C with 5% CO2. Cells were passaged in our laboratory
for lesser than 6 months after resuscitation. Mycoplasma contamination was
tested by PCR during culture, and no additional authentication was done
as cells came from national repositories. Cells were grown to 70–80%
confluence, and incubated with the constructed lentiviral vectors for 24 h in
growth medium containing 8 mg/ml of polybrene (Santa Cruz). Seventy-two
hours after infection, the medium was changed to fresh RPMI1640 containing
10 mg/ml puromycin (Santa Cruz). Puromycin-resistant colonies were used for
subsequent studies.
Cell proliferation and colony formation assay. Cell proliferation was
determined by [3H]-thymidine incorporation assay, as we previously reported.51
Colony formation assay was used to determine the anchorage-dependent
growth property of the cells and was performed, as described previously.52
Briefly, Jagged1 knockdown and the control cells were plated in six-well plates
at a density of 3000 cells/well. Plates were incubated for 7 days, and cell
colonies were visualized by staining with crystal violet and macroscopically
counted.
Cell cycle analysis. Cell cycle was detected by propidium iodide (PI) staining
and flow cytometric analysis. Briefly, cells were washed with PBS, fixed with 70%
ethanol at 4 1C overnight. After washing with PBS, cells were re-suspended in
50mg/ml -of PI containing 0.5% Triton-X 100 and 100mg/ml of RNase A and
incubated in the dark at 37 1C for 30 min. The cells were then analyzed for DNA
content using a FACS Calibur Cytometer (BD Biosciences). A minimum of 10 000
events per sample was acquired and subsequently analyzed with ModFit software
(Verity Software House, Topsham, ME, USA).
Cell migration and invasion assay. Cell migration was analyzed by a
conventional wound-healing assay, as described previously.53 Briefly, Jagged1-
shRNA or scrambled-shRNA stably infected cells were grown in six-well plates
to complete confluence. Wound injury was made with the tip of a sterile
micropipette, and detached cells were removed by washing with PBS. Cells
were then incubated and allowed to migrate for up to 72 h. Photographs
were taken and migration index was calculated as follows: migration index¼
[(initial wound width–width of wound at time point tested)/initial wound
width] 100%.
In vitro invasion assay was performed using a 24-well transwell insert (8 mm pore
size) pre-coated with BD Matrigel matrix (BD Biosciences) according to the
manufacturer’s instruction. Cells transfected with Jagged1-shRNA or scrambled-
shRNA were seeded into the upper chamber in serum-free medium at a density of
50 000 cells/well. The medium containing 10% FBS was placed in the lower
chamber to act as a chemoattractant, and cells were further incubated for the
indicated time. Non-invading cells were removed from the upper chamber and the
invaded cells remaining on the lower surface of the insert were fixed and stained
with crystal violet. Cells were quantified as the average number of cells found in five
random microscopic fields in three independent inserts.
Western blot and qPCR assays. Cells were lysed in RIPA buffer
(Sigma, St. Louis, MO, USA) supplemented with 1% protease inhibitor cocktail.
Proteins from the cell lysate were separated on a 10% SDS-PAGE and transferred
onto polyvinylidenedifluoride membranes (Millipore, Billerica, MA, USA). After
blocking, the membranes were probed with appropriate antibodies and detected
with Enhanced Chemiluminescence Assay (Pierce Biotechnology, Rockford,
IL, USA).
For the gene expression at the mRNA level, total RNA was extracted, quantified,
and converted to cDNA, and qPCR was performed using SYBR Green (Applied
Biosystems, Foster City, CA, USA) system. The sequences of primers used in
qPCR were as follows: JAGGED1 forward: 50-TCGGGTCAGTTCGAGTTGGA-30
and reverse: 50-CGTTCACGTTCTGCATGGAC-30; PCNA forward: 50-GCGTG
AACCTCACCAGTATGT-30 and reverse: 50-TCTTCGGCCCTTAGTGTAATGAT-30;
Ki67 forward: 50-ACGCCTGGTTACTATCAAAAGG-30 and reverse: 50-CAGACC
CATTTACTTGTGTTGGA-30; c-MYC forward: 50-GGCTCCTGGCAAAAGGTCA-30
and reverse: 50-CTGCGTAGTTGTGCTGATGT-30; MMP2 forward: 50-TACAGGAT
CATTGGCTACACACC-30 and reverse: 50-GGTCACATCGCTCCAGACT-30; MMP9
forward: 50-TGTACCGCTATGGTTACACTCG-30 and reverse: 50-GGCAGGGAC
AGTTGCTTCT-30; HES1 forward: 50-ACGTGCGAGGGCGTTAATAC-30 and
reverse: 50-GGGGTAGGTCATGGCATTGA-30; CD31 forward: 50-ACAGTGTTGA
CATGAAGAGCC-30 and reverse: 50-TGTAAAACAGCACGTCATCCTT-30;GAPDH
forward: 50-CTGGGCTACACTGAGCACC-30 and reverse: 50-AAGTGGTCGTTG
AGGGCAATG-30. The relative quantification of mRNA was normalized to
GAPDH.
Xenograft tumorigenesis in nude mice. Athymic nude mice (BALB/c
nu/nu) (male, 6–8-week-old) were purchased from the Academy of Military Medical
Science (Beijing, China), and were acclimated for 7 days in the laboratory before
experimentation. To establish xenograft tumors, 1 107 Jagged1 knockdown and
the control HCT15 cells were injected subcutaneously into the dorsal flanks of the
mice. Tumor volumes were calculated every 3 days according to the following
formula: volume (mm3)¼ [(shortest diameter)2 longest diameter]/2. On the day
of harvest the tumor tissues were excised, size was measured and weight was
determined. Harvested tumor tissues were either snap frozen for RNA analysis or
fixed in 10% neutral formalin for histology assay. All animal experiments were
approved by the Committee on the Use of Live Animals in Teaching and Research
of the Tianjin Medical University.
Statistical analysis. Data were expressed as mean±S.D. Student’s
independent two-sample t-tests were used for comparisons. A P value of
o0.05 was considered statistically significant.
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